Luna Innovations, Inc. (NASDAQ:LUNA)
| CAPS Rating |
|
|---|---|
| Open | $1.72 |
| Previous Close | $1.75 |
| Daily Range | $1.72 - $1.77 |
| 52-Week Range | $1.00 - $3.60 |
| Market Cap | $24.05M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 7,647 |
| Average Daily Volume | 0 |
LUNA
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
LUNA Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
LUNA News and Commentary
- Luna Innovations' CEO Discusses Q2 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Luna Innovations' CEO Discusses Inc.Q1 2010 Results - Earnings Call Transcript – SeekingAlpha
- Luna Innovations' CEO Discusses Inc.Q1 2010 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Luna Innovations, Incorporated CEO Discusses Q4 2010 Results - Earnings Call Transcript – SeekingAlpha
- Luna Innovations, Incorporated CEO Discusses Q4 2010 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Luna Innovations CEO Discusses Q3 2010 Results – Earnings Call Transcript – SeekingAlpha
- Luna Innovations CEO Discusses Q3 2010 Results – Earnings Call Transcript – SeekingAlpha Transcripts
- Luna Innovations Incorporated Q2 2010 Earnings Call Transcript – SeekingAlpha
- Luna Innovations Incorporated Q2 2010 Earnings Call Transcript – SeekingAlpha Transcripts
- The 50 Cent Club - June 21, 2010 – Blog at The Motley Fool
- UPDATE 1-Luna, Hansen to settle lawsuit; shares soar – Reuters
- Luna Innovations, Inc. (LUNA) – Blog at The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
RSS Headlines
Fool UK
